Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
February 22, 2007

Ikaria and Investor Group to Acquire INO Therapeutics for $670M

  • Ikaria Holdings will merge with INO Therapeutics in a transaction valued at approximately $670 million.

    INO Therapeutics is being acquired from The Linde Group, which will retain an equity position in the new entity. The combined company, which will be called Ikaria Holdings, will focus on therapeutic gases and critical care medicine. Its corporate headquarters will be in Clinton, NJ.

    "The merger of Ikaria and INO Therapeutics creates a fully integrated critical care therapeutics company with more than 300 employees, exceptional growth opportunities, and the capability to significantly improve critical care for newborns and other patients in thousands of hospitals around the world," says David Shaw, chairman and CEO-designate of the combined Ikaria entity.

  • Finally! A cure for the Biotech News Blues.

  • Join 110,000 colleagues who rely on GEN Highlights for breaking news and exclusive articles shaping today’s life science tools and technologies.

  • Oops! Please type your email in the following format: [email protected] An error has occurred. Please contact Customer Service at [email protected]
  • You’re all set! Thank you for subscribing to GEN Highlights.